RadOnc Smart Review

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 30 is the comprehensive Thoracic mock oral. Three case blocks cover metastatic disease with consolidation versus oligoprogression, superior vena cava syndrome and thymic carcinoma, and a post-treatment pulmonary syndrome followed by thoracic reirradiation decisions. Each case includes a contrasting twist that changes the recommendation.
Pause before every model answer. Lead with the diagnosis or differential, known extent, and immediate problem; state intent before technique; name the management-changing unknown; and carry the plan through sequencing, radiation details, toxicity, surveillance, salvage, and the point at which the treatment goal must change.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 29 is a board-synthesis workshop built around the order of operations that keeps thoracic decisions safe. We move from diagnosis and stage uncertainty to management-changing workup, invasive staging, operability, resectability, treatment intent, multimodality sequence, radiation indication, planning priorities, toxicity, surveillance, and salvage.
The disease-specific path changes across non-small cell lung cancer, small cell lung cancer, thymic tumors, mesothelioma, metastatic disease, palliation, toxicity, and reirradiation—but the decision discipline should remain portable.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 28 approaches thoracic reirradiation as a new treatment decision made in the shadow of a prior course. Before discussing dose, we define intent, alternatives, expected benefit, prior-plan reconstruction, registration uncertainty, cumulative exposure, and the organ that could turn an elegant plan into a catastrophic event.
The episode provides a framework for balancing meaningful local control against potentially irreversible or fatal toxicity, communicating uncertainty honestly, and recognizing when cumulative central-organ risk makes another strategy safer.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 27 tackles thoracic toxicity as a differential-diagnosis problem. Cough, dyspnea, dysphagia, fever, fatigue, chest discomfort, and palpitations may reflect radiation injury, infection, recurrent cancer, airway obstruction, cardiac disease, dehydration, systemic therapy, or more than one process at once.
Using a post-chemoradiation patient with evolving pulmonary and swallowing symptoms, we practice stability assessment, severity grading, treatment reconstruction, comparison with delivered dose, testing of dangerous alternatives, interruption and escalation decisions, and documentation of uncertainty with a clear reassessment endpoint.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 26 treats pleural mesothelioma as the surface-spreading disease it is—not as a spherical lung mass. We cover diagnostic adequacy, histology, anatomic extent, operability, and whether meaningful cytoreduction is achievable before turning to the radiation problem.
Planning then branches by operation. After lung-sparing pleurectomy and decortication, two lungs remain around a large concave pleural target; after extrapleural pneumonectomy, one lung remains and even a modest low-dose bath can be dangerous. The recommendation must begin with the actual operation and expected pulmonary risk.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 25 uses thymic malignancies to build a disciplined approach to rare thoracic tumors. We address diagnostic pathways, myasthenic symptoms, biopsy-route hazards, the difference between operability and an R0 resection, true invasion versus simple contact, postoperative radiation selection, and reconstruction of the tumor bed.
The larger lesson is how to reason when evidence is sparse: avoid automatic extrapolation from common lung cancer, state uncertainty honestly, and build a recommendation from anatomy, pathology, surgical findings, recurrence risk, and achievable treatment geometry.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 24 brings structure to thoracic palliation and oncologic emergencies. We balance the danger of moving too slowly during airway, vascular, spinal-cord, pericardial, or respiratory compromise against the harm of giving empiric radiation to a stable patient before preserving diagnosis, stage, and the best procedural or systemic option.
The episode emphasizes stabilization first, then intervention matched to mechanism and time horizon. Radiation may be central, adjunctive, delayed until tissue is obtained, or unnecessary when another treatment is more direct.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 23 separates two often-confused strategies in limited metastatic non-small cell lung cancer: comprehensive treatment of every known site after systemic control and ablation of a resistant site during otherwise effective therapy. A lesion count alone is not a biological diagnosis or a treatment indication.
Using a thoracic primary with limited adrenal and bone disease as the anchor, we examine diagnostic confidence, systemic response, disease pace, technical feasibility, cumulative toxicity, and whether local therapy truly complements the systemic strategy rather than delaying recognition of widespread failure.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 22 focuses on integrating radiation and systemic therapy in metastatic non-small cell lung cancer without allowing two independent treatment calendars to collide. The durable skill is not memorizing one universal drug-hold table, but making a transparent risk decision for the exact agent, target, dose per fraction, organ exposure, urgency, and prior toxicity.
We also define ownership: who pauses treatment, what evidence is required to restart, and how to balance radiation benefit against the consequences of interrupting an effective systemic therapy.

Welcome back to Rad Onc Smart Review: Thoracic Oncology Edition.
Episode 21 is a three-block mock oral covering fit unresectable stage III non-small cell lung cancer, frail unresectable stage III disease, and small cell lung cancer. The cases test concurrent versus modified chemoradiation, planning and toxicity management, post-treatment selection, brain-directed decisions, surveillance, and salvage.
Pause before each answer. Lead with diagnosis, stage framework, and intent; identify the stage-driving evidence; distinguish operability from resectability; then defend the treatment sequence, radiation plan, organ-at-risk tradeoffs, interruption strategy, and the finding that would change your recommendation.